Duchenne Muscular Dystrophy (DMD) Drugs Market - By Drug Type (Exon Skipping Drugs, Corticosteroids, Gene Therapy), Route of Administration (Oral, Injectable), Competitive Landscape – Global Forecast (2024 – 2032)

Duchenne Muscular Dystrophy Drugs Market Size

Duchenne Muscular Dystrophy Drugs Market size was valued at USD 3.2 billion in 2023 and is estimated to grow at 11.6% CAGR between 2024 to 2032. The market has seen considerable growth due to the increasing burden of DMD and rising demand for for novel therapies.
 

For instance, according to data from the Muscular Dystrophy Association Inc., in June 2023, DMD prevalence in Europe and North America was approximately 6 per 100,000 individuals. Similarly, a study published in the PLOS One Journal, reported a general population prevalence ranging from 1.7 to 3.4 cases per 100,000 individuals, with a birth prevalence of 21.7 to 28.2 cases per 100,000 live male births. Thus, rising prevalence of these cases increases the demand for effective therapeutics, thereby driving market growth.
 

Furthermore, growing involvement of pharmaceutical companies in DMD drug development, coupled with strategic collaborations and partnerships, is accelerating innovation and market expansion. Moreover, increasing awareness, supportive regulatory frameworks, and collaborations between academia and pharmaceutical companies are expected to further accelerate the development and adoption of novel therapies in the global Duchenne muscular dystrophy (DMD) drugs market.
 

Duchenne muscular dystrophy (DMD) drugs refer to pharmaceutical treatments aimed at managing and potentially alleviating symptoms of DMD, a rare genetic disorder characterized by progressive muscle degeneration and weakness. These drugs target the underlying genetic mutation or associated symptoms, such as inflammation and deterioration of muscle function. They include corticosteroids like prednisone and deflazacort, exon skipping drugs such as eteplirsen and golodirsen, and emerging therapies like gene editing techniques and others.
 

Duchenne Muscular Dystrophy Drugs Market Trends

Increasing research and development (R&D) funding significantly drives the DMD drugs market by catalyzing innovation and accelerating the development of novel therapies. Expanded funding supports enable pharmaceutical companies and research institutions to explore advanced treatment modalities such as gene therapy, exon skipping, and gene editing technologies.
 

• For instance, in January 2023, Parent Project Muscular Dystrophy (PPMD) announced a strategic investment of USD 500,000 in Myosana Therapeutics Inc. to support the development and deployment of its non-viral gene therapy delivery platform. This initiative aimed to mitigate skeletal muscle degeneration and address DMD-related heart failure.
   
• Thus, as DMD cases increase and R&D investments grow, the demand for effective treatments is expected to rise, potentially fostering market growth.
   

Duchenne Muscular Dystrophy Drugs Market Analysis

Based on the drug type, the market is categorized as exon skipping drugs, corticosteroids, gene therapy, and other drug types. The corticosteroids segment is set to lead the market, accounting for the largest revenue of USD 1.2 billion, anticipating its dominance throughout the forecast period with a CAGR of 11.4%.
 

• High market share of corticosteroids can be attributed to their well-established efficacy in slowing the progression of the disease. Prednisone and deflazacort, the most used corticosteroids, are pivotal in managing DMD by improving muscle strength and function, delaying the loss of ambulation, and reducing the risk of scoliosis and respiratory complications.
   
• The widespread adoption of these drugs is driven by their ability to modulate inflammation and improve clinical outcomes, combined with extensive clinical research supporting their benefits.
   
• Additionally, the relatively lower cost and accessibility of corticosteroids compared to newer, more expensive therapies contribute to their dominant market position.

Based on route of administration, the DMD drugs market is classified into oral and injectable. The oral segment held a market share of 66.5% in 2023 and is expected to maintain dominance throughout the analysis period.
 

• Oral medications provide convenience and ease of administration compared to injectable or infusion-based therapies, which is especially important for pediatric patients.
   
• Additionally, advancements in oral formulations provide effective disease management.
   
• Thus, the increased patient compliance and preference for non-invasive treatments have significantly contributed to the growth and accessibility of DMD therapies, making the oral route the preferred choice in the market.

U.S. dominated the North American Duchenne muscular dystrophy drugs market accounting for USD 1.3 billion in 2023 and is anticipated to show considerable growth over the analysis period.
 

• The U.S. holds a prominent position in the North American market due to the high prevalence of DMD, and substantial funding for research anticipating launches of attractive pipeline candidates.
   
• For instance, in March 2204, Catalyst Pharmaceuticals, Inc. announced the U.S. commercial launch of AGAMREE oral suspension 40 mg/mL for treating DMD in patients aged two years and older. Following FDA approval on October 26, 2023, AGAMREE is now available by prescription and dispensed countrywide through a specialty pharmacy network in the U.S. This launch marked a significant breakthrough in expanding treatment options for DMD patients in the U.S., enhancing access to vital therapies.
   
• Additionally, patient advocacy groups and government initiatives further bolster market growth, ensuring rapid advancements and improved access to cutting-edge treatments for DMD patients.
   

Germany exhibited a high growth potential in the European duchenne muscular dystrophy drugs market.
 

• The country's robust healthcare infrastructure and advanced research capabilities foster the development and adoption of innovative DMD treatments.
   
• Government initiatives and funding for rare disease research have also played a crucial role in accelerating clinical trials and regulatory approvals for new therapies.
   
• Additionally, the presence of leading pharmaceutical companies and collaborative efforts between academic institutions and industry stakeholders enhance Germany's capacity to bring novel DMD drugs to market.
   

The Asia Pacific DMD drugs market is poised for rapid growth with a CAGR of 12% during the forecast period.
 

• Asia Pacific is poised for rapid growth due to increasing awareness, improved diagnostic capabilities, and rising healthcare expenditure.
   
• Countries like Japan, China, and India are witnessing increased R&D activities, with several biotech companies and academic institutions focusing on development novel therapies, further drives growth in the Asia Pacific region.
   
• For instance, researchers in India are developing an affordable treatment for DMD. The Indian Institute of Technology (IIT) Jodhpur, in collaboration with the Dystrophy Annihilation Research Trust (DART) and AIIMS Jodhpur, has established a research center to create cost-effective therapeutics. This initiative is aimed to make treatment more accessible and affordable for affected families.
   
• Furthermore, growing government initiatives and supportive regulatory frameworks are also fostering growth in this market.
   

Duchenne Muscular Dystrophy Drugs Market Share

The Duchenne muscular dystrophy (DMD) drugs market is characterized by intense R&D activities focused on innovative therapeutic approaches. The key players in the market are heavily investing in gene therapy, exon skipping drugs, and other advanced technologies to address the genetic mutations underlying DMD. In addition, the market competition is further driven by the pursuit of treatments that improve muscle function and delay disease progression. Furthermore, regulatory approvals, strategic partnerships, and clinical trial outcomes play pivotal roles in shaping market dynamics, influencing market penetration, and competitive positioning of therapies.
 

Duchenne Muscular Dystrophy Drugs Market Companies

Few of the prominent players operating in the Duchenne muscular dystrophy drugs industry include:

• Aurobindo Pharma
• Capricor Therapeutics, Inc.
• Catalyst Pharmaceuticals Inc.
• EspeRare Foundation
• FibroGen, Inc.
• Italfarmaco S.p.A
• NS Pharma
• PTC Therapeutics, Inc.
• Santhera Pharmaceuticals
• Sarepta Therapeutics, Inc.
• Solid Biosciences Inc.
   

Duchenne Muscular Dystrophy (DMD) Drugs Industry News:

• In June 2024, Sarepta Therapeutics, Inc. received the U.S. Food and Drug Administration (FDA) approval for the expansion of Elevidys, a gene therapy for DMD, to include both ambulatory and non-ambulatory individuals aged 4 and older with a confirmed DMD gene mutation. This broader approval marked a significant advancement in DMD treatment options, enhancing accessibility for a wider patient population.
   
• In January 2024, Solid Biosciences Inc. secured orphan drug designation (ODD) from the U.S. FDA for SGT-003, its next-generation gene therapy candidate for DMD. This achievement, alongside the recent Fast Track Designation, accelerated their efforts to combat the disease effectively.
   

The Duchenne muscular dystrophy drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Exon skipping drugs
• Corticosteroids
• Gene therapy
• Other drug types

Market, By Route of Administration

• Oral
• Injectable

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • The Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa